{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-011887","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.148381+00:00","generated_at":"2026-06-24T04:53:29.847345+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M","bullets":["Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.","GAAP net loss of $45.5M ($0.96 EPS) vs loss of $17.5M ($0.38) in Q2 2021; includes $10M IPR&D charge for iVeena licensing.","Non-GAAP net loss of $39.1M ($0.83) vs $10.1M ($0.22) in prior year.","Raised 2022 net sales guidance to $275-280M from prior $270-275M.","Ended Q2 with ~$400M cash and short-term investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-011887","json":"https://secwatch.observer/filing/0001558370-22-011887.json","markdown":"https://secwatch.observer/filing/0001558370-22-011887.md","text":"https://secwatch.observer/filing/0001558370-22-011887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/0001558370-22-011887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/gkos-20220803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:53:29.847345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}